Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Boston Millennia Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
Boston Millennia Partners

Boston Millennia Partners

Operating

Boston-based financial firm providing growth equity financing to healthcare and business services for 30+ years.

Location
Boston, MA, US
Founded
1982
Firm
Compare
Portfolio
Employees

Investments

Kaid Health
Kaid Health

Total Raised

$5.8M

Rounds

3

Series UnknownDecember 2023
Series A$4.3MMay 2022
Korio
Korio

Total Raised

$6.8M

Rounds

1

Series Unknown$6.8MOctober 2023
Atropos Health
Atropos Health

Total Raised

$14M

Rounds

3

Series A$14MAugust 2022
CubeWorks
CubeWorks

Total Raised

$7.2M

Rounds

5

Seed$2.4MJune 2022
Huma.AI
Huma.AI

Total Raised

$11.9M

Rounds

4

Series A$9.5MFebruary 2022
Reveleer
Reveleer

Total Raised

$143.8M

Rounds

10

Series Unknown$65MDecember 2021
Series CJanuary 2020
Series C$5.5MNovember 2019
CareAlign
CareAlign

Total Raised

$3.8M

Rounds

3

Seed$2.3MNovember 2021
Seed$1MJuly 2020
Bekhealth
Bekhealth

Total Raised

$11.1M

Rounds

3

Seed$4MJune 2021
Clinical Research IO
Clinical Research IO

Total Raised

$19M

Rounds

6

Series A$3.5MFebruary 2021
Cota Healthcare
Cota Healthcare

Total Raised

$109M

Rounds

7

Series D$34MNovember 2020
Series C$40MFebruary 2018
Series B$18MDecember 2016
Cecelia Health
Cecelia Health

Total Raised

$22.4M

Rounds

6

Series B$13MAugust 2020
Roobrik
Roobrik

Total Raised

$5M

Rounds

4

Seed$1.4MSeptember 2018
Mingle Health
Mingle Health

Total Raised

$15.3M

Rounds

5

Series UnknownJanuary 2018
C2Sense
C2Sense

Total Raised

$28.4M

Rounds

6

Seed$3.2MSeptember 2017
Collegium Pharmaceutical
Collegium Pharmaceutical
Public

Total Raised

$309.2M

Rounds

10

Private Equity$50MMarch 2015
Series B$22.5MFebruary 2012
Series D$20MJuly 2008
Cardiomems
Cardiomems
Public

Total Raised

$232.6M

Rounds

10

Series Unknown$37.9MMay 2010
Series F$22.1MOctober 2009